What are the precautions for palbociclib/palbociclib/palbociclib?

Palbociclibis not a traditional form of chemotherapy(chemo). Palbocicillin is a "targeted drug therapy" known as a CDK 4/6 inhibitor. Palbocicillin plus aromatase inhibitor Femara (letrozole) as initial endocrine therapy in postmenopausal women and men. In combination with the estrogen receptor antagonist Faslodex(fulvestrant)for patients with disease progression after endocrine therapy. According to current standards of clinical practice, palbocicillin plus fulvestrant and a luteinizing hormone-releasing hormone (LHRH) agonist are used to suppress ovarian function in premenopausal women.

What are the precautions?

1.Neutropenia

Neutropenia was the most commonly reported adverse reaction in PALOMA-2 and PALOMA-3, with incidence rates of 80% and 83%, respectively. In PALOMA-2, 66% of patients who received palbocicillin plus letrozole and in PALOMA -3In 66%of patients who received ibrune plus fulvestrant reported a ≥3 grade decrease in neutrophil count. In PALOMA-2 and PALOMA-3, the median time to first onset of any grade neutropenia was 15 days, and the median duration of grade ≥3 neutropenia was 7 days. Monitor complete blood counts before initiating treatment with IBRANCE and at the beginning of each cycle, and on Day 15 of the first two cycles, as clinically indicated. For occurrences of 3 or For patients with Grade 4 neutropenia, dose interruption, dose reduction, or delay in starting the treatment cycle is recommended. Febrile neutropenia occurred in 1.8% of PALOMA-2 and PALOMA-3 patients. One death due to neutropenic sepsis was observed in PALOMA-3. Physicians should inform patients to promptly report any fever symptoms.

2.Interstitial lung disease(ILD)/Pneumonia

Receive cyclin-dependent kinase4/6 (CDK4/6)Severe, life-threatening or fatal interstitial lung disease(ILD) and / or pneumonitis may occur in patients treated with inhibitors, including IBRANCE when used in combination with endocrine therapy. Across all clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% ofIBRA NCEpatients treated with ILD/pneumonia of any grade developed, 0.1% of patients developed grade 3 or grade 4, and no deaths were reported. Additional cases of ILD/pneumonia have been observed in the post-marketing setting, and deaths have been reported. Monitor patients for ILD/pulmonary symptoms of pneumonia (such as hypoxia, cough, dyspnea). If a patient develops new or worsening respiratory symptoms and is suspected of having pneumonia, ibra should be discontinued immediately and the patient evaluated. Patients with severe ILD or pneumonia should permanently discontinue this product.

3.Embryo-Fetal toxicity

Based on findings from animal studies and its mechanism of action, palbocicillin can cause fetal harm when given to pregnant women. In animal reproduction studies, administration of palbocicillin to pregnant rats and rabbits during organogenesis resulted in fetal toxicity to maternally exposed embryos ≥ human clinical exposure based on area under the curve (AUC) 4times. Inform pregnant women of potential risks to the fetus. Advise females of reproductive potential to use effective contraception during treatment with palbocicillin and for at least 3 weeks after the last dose. Original drugs in Hong Kong cost around 1 million, while generic drugs cost around 7more than 7more than 4 more than 1,000 per box. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.